| 國立成功大學 |
2022 |
In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodst
|
Liu, P.-Y.;Ko, W.-C.;Lee, W.-S.;Lu, P.-L.;Chen, Y.-H.;Cheng, S.-H.;Lu, M.-C.;Lin, C.-Y.;Wu, T.-S.;Yen, M.-Y.;Wang, L.-S.;Liu, C.-P.;Shao, P.-L.;Lee, Y.-L.;Shi, Z.-Y.;Chen, Y.-S.;Wang, F.-D.;Tseng, S.-H.;Lin, C.-N.;Chen, Y.-H.;Sheng, W.-H.;Lee, C.-M.;Tang, H.-J.;Hsueh, P.-R. |
| 國立成功大學 |
2022 |
Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019
|
Tsai, Y.-T.;Lee, Y.-L.;Lu, M.-C.;Shao, P.-L.;Lu, P.-L.;Cheng, S.-H.;Ko, W.-C.;Lin, C.-Y.;Wu, T.-S.;Yen, M.-Y.;Wang, L.-S.;Liu, C.-P.;Lee, W.-S.;Shi, Z.-Y.;Chen, Y.-S.;Wang, F.-D.;Tseng, S.-H.;Lin, C.-N.;Chen, Y.-H.;Sheng, W.-H.;Lee, C.-M.;Tang, H.-J.;Lin, C.-Y.;Chen, Y.-H.;Hsueh, P.-R. |
| 臺大學術典藏 |
2021-11-30T04:54:31Z |
The relationship between aminoterminal propeptide of type III procollagen and heart rate variability parameters in heart failure patients: A potential serum marker to evaluate cardiac autonomic control and sudden cardiac death
|
Lin Y.-H.; Lin C.; Lo M.-T.; Lin H.-J.; Wu Y.-W.; Hsu R.-B.; Chao C.-L.; Hsu H.-C.; Wang P.-C.; VIN-CENT WU; Wang S.-S.; Lee C.-M.; Chien K.-L.; Ho Y.-L.; Chen M.-F.; Peng C.-K. |
| 臺大學術典藏 |
2021-09-27T05:32:42Z |
Nationwide surveillance of antimicrobial resistance in invasive isolates of Streptococcus pneumoniae in Taiwan from 2017 to 2019
|
Tsai Y.-T.; Lee Y.-L.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Cheng S.-H.; Ko W.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Tang H.-J.; Lin C.-Y.; Chen Y.-H.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-27T05:32:41Z |
In vitro activity of cefiderocol, cefepime/enmetazobactam, cefepime/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated from bloodstream infection in Taiwan between 2018–2020
|
Liu P.-Y.; Ko W.-C.; Lee W.-S.; Lu P.-L.; Chen Y.-H.; Cheng S.-H.; Lu M.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Shao P.-L.; Lee Y.-L.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Tang H.-J.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-27T05:32:39Z |
Antimicrobial susceptibility of bacteremic vancomycin-resistant Enterococcus faecium to eravacycline, omadacycline, lipoglycopeptides, and other comparator antibiotics: Results from the 2019–2020 Nationwide Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART)
|
Tsai H.-Y.; Lee Y.-L.; Liu P.-Y.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Cheng S.-H.; Ko W.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Chen Y.-H.; Liao C.-H.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-27T05:32:37Z |
In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017–2020
|
Lee Y.-L.; Ko W.-C.; Lee W.-S.; Lu P.-L.; Chen Y.-H.; Cheng S.-H.; Lu M.-C.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Shao P.-L.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Lin C.-N.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Tang H.-J.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-27T05:32:37Z |
National surveillance of antimicrobial susceptibilities to dalbavancin, telavancin, tedizolid, eravacycline, omadacycline and other comparator antibiotics and serotype distribution of invasive Streptococcus pneumoniae isolates in adults: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) programme in 2017–2020
|
Chien Y.-C.; Lee Y.-L.; Liu P.-Y.; Lu M.-C.; Shao P.-L.; Lu P.-L.; Cheng S.-H.; Lin C.-Y.; Wu T.-S.; Yen M.-Y.; Wang L.-S.; Liu C.-P.; Lee W.-S.; Shi Z.-Y.; Chen Y.-S.; Wang F.-D.; Tseng S.-H.; Chen Y.-H.; WANG-HUEI SHENG; Lee C.-M.; Chen Y.-H.; Ko W.-C.; Hsueh P.-R. |
| 臺大學術典藏 |
2021-09-04T06:12:14Z |
HBsAg profiles in patients receiving peginterferon alfa-2a plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses
|
Yu M.-L.; Lee C.-M.; Chuang W.-L.; Lu S.-N.; Dai C.-Y.; Huang J.-F.; Lin Z.-Y.; Hu T.-I.; Chen C.-H.; Hung C.-.; Wang J.-H.; Chen C.-L.; JIA-HORNG KAO; Lai M.-Y.; Liu C.-H.; Su T.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; Chen P.-J.; Liu C.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:12:12Z |
Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease
|
Keating G.M.; Buti M.; Gadano A.; JIA-HORNG KAO; Lee C.-M.; Peng C.-Y.; Schiff E.R.; Tanwandee T. |
| 臺大學術典藏 |
2021-09-04T06:12:12Z |
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses
|
Yeh M.-L.; Hung C.-H.; Huang J.-F.; Liu C.-J.; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2021-09-04T06:11:51Z |
Sustained hepatitis C virus clearance and increased hepatitis B surface antigen seroclearance in patients with dual chronic hepatitis C and B during posttreatment follow-up
|
Yu M.-L.; Lee C.-M.; Chen C.-L.; Chuang W.-L.; Lu S.-N.; Liu C.-H.; Wu S.-S.; Liao L.-Y.; Kuo H.-T.; Chao Y.-C.; Tung S.-Y.; Yang S.-S.; JIA-HORNG KAO; Su W.-W.; Lin C.-L.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Liu C.-J. |
| 臺大學術典藏 |
2021-09-04T05:17:05Z |
Phase IV randomized clinical study: Peginterferon alfa-2a with adefovir or entecavir pre-therapy for HBeAg-positive chronic hepatitis B
|
Hsu C.-W.; Su W.-W.; Lee C.-M.; Peng C.-Y.; Chuang W.-L.; JIA-HORNG KAO; Chu H.-C.; Huang Y.-H.; Chien R.-N.; Liaw Y.-F. |
| 臺大學術典藏 |
2021-09-04T05:16:57Z |
Taiwan consensus statement on the management of chronic hepatitis B
|
Chien R.-N.; JIA-HORNG KAO; Peng C.-Y.; Chen C.-H.; Liu C.-J.; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; Ni Y.-H.; Chuang W.-L.; Lee C.-M.; Wu J.-C.; Chen P.-J.; Liaw Y.-F. |
| 臺大學術典藏 |
2021-09-01T01:54:03Z |
Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma
|
Yen C.-H.; Lu Y.-C.; Li C.-H.; Lee C.-M.; Chen C.-Y.; Cheng M.-Y.; Huang S.-F.; Chen K.-F.; ANN-LII CHENG; Liao L.-Y.; Lee Y.-H.W.; Chen Y.-M.A. |
| 臺大學術典藏 |
2021-08-31T01:31:02Z |
Fulminant primary cardiac lymphoma with sudden cardiac death: A case report and brief review
|
Cheng J.-F.; Lee S.-H.; Hsu R.-B.; Yu S.-C.; Shun C.-T.; PANG-SHUO HUANG; Chen Y.-H.; Lee C.-M. |
| 臺大學術典藏 |
2021-08-24T06:21:25Z |
Relationship between Bone Mineral Density and Serum Osteoprotegerin in Patients with Chronic Heart Failure
|
Chen Y.-H.; Wu Y.-W.; Yang W.-S.; Wang S.-S.; Lee C.-M.; Chou N.-K.; Hsu R.-B.; Lin Y.-H.; MAO-SHIN LIN; Ho Y.-L.; Chen M.-F. |
| 臺大學術典藏 |
2021-08-24T06:21:19Z |
Everolimus-eluting bioresorbable vascular scaffold in real world practice - A single center experience
|
Liang H.-W.; Kao H.-L.; Lin Y.-H.; Hwang J.-J.; MAO-SHIN LIN; Chiang F.-T.; Lee C.-M.; Yeh C.-F.; Wang T.-D.; Wu C.-K.; Lin L.-Y.; Tsai C.-T.; Chen Y.-H. |
| 臺大學術典藏 |
2021-08-16T08:36:23Z |
Etiology of pulmonary complications of human immunodeficiency virus-1-infected patients in Taiwan in the era of combination antiretroviral therapy: A prospective observational study
|
Lee K.-Y.; Ho C.-C.; Ji D.-D.; Lee C.-M.; Tsai M.-S.; ARISTINE CHENG; Chen P.-Y.; Tsai S.-Y.; Tseng Y.-T.; Sun H.-Y.; Lee Y.-C.; Hung C.-C.; Chang S.-C. |
| 臺大學術典藏 |
2021-08-05T02:40:50Z |
Challenges toward Low-Power SOT-MRAM
|
Lin S.-J;Huang Y.-L;Song M;Lee C.-M;Xue F;Chen G.-L;Yang S.-Y;Chang Y.-J;Wang I.-J;Hsin Y.-C;Su Y.-H;Wei J.-H;Pai C.-F;Wang S.X;Diaz C.H.; Lin S.-J; CHI-FENG PAI et al. |
| 臺大學術典藏 |
2021-07-16T08:28:52Z |
Prostaglandin E2 potentiates mesenchymal stem cell-induced IL-10+IFN-γ+CD4+ regulatory T cells to control transplant arteriosclerosis
|
WAN-TSENG HSU; Lin C.-H.; Chiang B.-L.; Jui H.-Y.; Wu K.K.-Y.; Lee C.-M. |
| 臺大學術典藏 |
2021-07-16T08:28:52Z |
Autologous Mesenchymal stem cells prevent transplant arteriosclerosis by enhancing local expression of interleukin-10, interferon-γ, and indoleamine 2,3-dioxygenase
|
Jui H.-Y.; Lin C.-H.; WAN-TSENG HSU; Liu Y.-R.; Hsu R.-B.; Chiang B.-L.; Tseng W.-Y.I.; Chen M.-F.; Wu K.K.; Lee C.-M. |
| 臺大學術典藏 |
2021-07-16T08:28:51Z |
CXCR4 antagonist TG-0054 mobilizes mesenchymal stem cells, attenuates inflammation, and preserves cardiac systolic function in a porcine model of myocardial infarction
|
WAN-TSENG HSU; Jui H.-Y.; Huang Y.-H.; Su M.-Y.M.; Wu Y.-W.; Tseng W.-Y.I.; Hsu M.-C.; Chiang B.-L.; Wu K.K.; Lee C.-M. |
| 臺大學術典藏 |
2021-07-16T08:28:50Z |
Drug-related problems vary with medication category and treatment duration in Taiwanese heart failure outpatients receiving case management
|
WAN-TSENG HSU; Shen L.-J.; Lee C.-M. |
| 臺大學術典藏 |
2021-07-16T08:28:49Z |
CXCR4 Antagonist Reduced the Incidence of Acute Rejection and Controlled Cardiac Allograft Vasculopathy in a Swine Heart Transplant Model Receiving a Mycophenolate-based Immunosuppressive Regimen
|
WAN-TSENG HSU; Lin C.-H.; Jui H.-Y.; Tseng Y.-H.; Shun C.-T.; Hsu M.-C.; Wu K.K.-Y.; Lee C.-M. |
